Sexual dimorphism in schizophrenia: Is there a need for gender-based protocols?

Expert Review of Neurotherapeutics

Volumn 11, Issue 7, 2011, Pages 951-959

  Mendrek, Adrianna ^a   Stip, Emmanuel ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

adjunct therapy; estrogen; schizophrenia; sex differences; sex steroid hormones; testosterone

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; NEUROLEPTIC AGENT; PROGESTERONE; SEX HORMONE; TESTOSTERONE;

BRAIN FUNCTION; BRAIN REGION; CLINICAL PROTOCOL; COGNITION; EMOTIONALITY; ESTROGEN BLOOD LEVEL; HUMAN; MENSTRUAL CYCLE; MENTAL HEALTH; NEUROPROTECTION; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

EID: 79959935363     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.78     Document Type: Review

References (122)

1. Andreasen NC, Carpenter WT Jr. Diagnosis and classification of schizophrenia. Schizophr Bull. 19(2), 199-214 (1993). (Pubitemid 23183145)
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 64(10), 1123-1131 (2007). (Pubitemid 47529346)
3. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 401, 3-38 (2000). (Pubitemid 30412890)
4. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int. Rev. Psychiatry 22(5), 417-428 (2010
5. Johnson J, Stewart DE. DSM-V: toward a gender sensitive approach to psychiatric diagnosis. Arch. Womens Ment. Health 13(1), 17-19 (2010).
6. Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr. Bull. 35(5), 937-948 (2009).
7. Lindamer LA, Lohr JB, Harris MJ, Jeste DV. Gender, estrogen, and schizophrenia. Psychopharmacol. Bull. 33(2), 221-228 (1997). (Pubitemid 27293111)
8. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl. 2), 17-54 (2003). (Pubitemid 36335819)
9. Flor-Henry P. Schizophrenia: sex differences. Can. J. Psychiatry 30(5), 319-322 (1985). (Pubitemid 15018103)
10. Tamminga CA. Gender and schizophrenia. J. Clin. Psychiatry 58(Suppl. 15), 33-37 (1997). (Pubitemid 28047253)
11. Ring N, Tantam D, Montague L et al. Gender differences in the incidence of definite schizophrenia and atypical psychosis - focus on negative symptoms of schizophrenia. Acta Psychiatr. Scand. 84(6), 489-496 (1991).
12. Schultz SK, Miller DD, Oliver SE et al. The life course of schizophrenia: age and symptom dimensions. Schizophr. Res. 23(1), 15-23 (1997). (Pubitemid 27095187)
13. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Gur RC. Gender differences in the clinical expression of schizophrenia. Schizophr. Res. 7(3), 225-231 (1992).
14. Andia AM, Zisook S, Heaton RK et al. Gender differences in schizophrenia. J. Nerv. Ment. Dis. 183(8), 522-528 (1995).
15. Szymanski S, Lieberman JA, Alvir JM et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry 152(5), 698-703 (1995).
16. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr. Bull. 30(2), 229-240 (2004). (Pubitemid 38828531)
17. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J. Clin. Psychiatry 66(11), 1468-1476 (2005). (Pubitemid 41779547)
18. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann. Intern. Med. 147(3), 149-155 (2007). (Pubitemid 351664594)
19. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin. Res. Cardiol. 95(3), 136-147 (2006).
20. Cubbon RM, Rajwani A, Abbas A et al. Hyperglycaemia, in relation to sex, and mortality after acute coronary syndrome. Eur. J. Cardiovasc. Prev. Rehabil. 14(5), 666-671 (2007 (Pubitemid 47556404)
21. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res. Treat. 98(3), 349-356 (2006). (Pubitemid 44195606)
22. Lin HC, Hsiao FH, Pfeiffer S, Hwang YT, Lee HC. An increased risk of stroke among young schizophrenia patients. Schizophr. Res. 101(1-3), 234-241 (2008).
23. Behl C. Estrogen can protect neurons: modes of action. J. Steroid Biochem. Mol. Biol. 83(1-5), 195-197 (2002). (Pubitemid 37040656)
24. Goff DC, Sullivan LM, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 80(1), 45-53 (2005). (Pubitemid 41587462)
25. Czlonkowska AI, Zienowicz M, Bidzinski A et al. The role of neurosteroids in the anxiolytic,antidepressive- and anticonvulsive effects of selective serotonin reuptake inhibitors. Med. Sci. Monit. 9(11), RA270-RA275 (2003). (Pubitemid 38128280)
26. Ostlund H, Keller E, Hurd YL. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann. NY Acad. Sci. 1007, 54-63 (2003). (Pubitemid 38258338)
27. Dluzen DE. Estrogen, testosterone, and gender differences. Endocrine 27(3), 259-267 (2005).
28. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol. Neurobiol. 16(3), 325-344 (1996). (Pubitemid 26231262)
29. Sherwin BB. Cognitive assessment for postmenopausal women and general assessment of their mental health. Psychopharmacol. Bull. 34(3), 323-326 (1998). (Pubitemid 28537954)
30. Sherwin BB. Surgical menopause, estrogen, and cognitive function in women: what do the findings tell us? Ann. NY Acad. Sci. 1052, 3-10 (2005). (Pubitemid 41338953)
31. Seeman MV. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21(2), 123-127 (1996). (Pubitemid 26121335)
32. Seeman MV. Psychopathology in women and men: focus on female hormones. Am. J. Psychiatry 154(12), 1641-1647 (1997). (Pubitemid 27516578)
33. Grigoriadis S, Seeman MV. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can. J. Psychiatry 47(5), 437-442 (2002). (Pubitemid 34792990)
34. Cohen RZ, Seeman MV, Gotowiec A, Kopala L. Earlier puberty as a predictor of later onset of schizophrenia in women. Am. J. Psychiatry 156(7), 1059-1064 (1999). (Pubitemid 29302800)
35. Chang SS, Renshaw DC. Psychosis and pregnancy. Compr. Ther. 12(10), 36-41 (1986). (Pubitemid 17210833)
36. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br. J. Psychiatry 150, 662-673 (1987). (Pubitemid 17061231)
37. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 37(10), 1427-1436 (2007). (Pubitemid 47581417)
38. Hallonquist JD, Seeman MV, Lang M, Rector NA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry 33(3), 207-209 (1993). (Pubitemid 23089970)
39. Gattaz WF, Vogel P, Riecher-Rossler A, Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol. Psychiatry 36(2), 137-139 (1994). (Pubitemid 24227269)
40. Hendrick V, Altshuler LL, Burt VK. Course of psychiatric disorders across the menstrual cycle. Harv. Rev. Psychiatry 4(4), 200-207 (1996). (Pubitemid 26418564)
41. Zhang-Wong JH, Seeman MV. Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arch. Womens Ment. Health 5(3), 93-98 (2002). (Pubitemid 35387786)
42. Huber TJ, Borsutzky M, Schneider U, Emrich HM. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr. Scand. 109(4), 269-274 (2004). (Pubitemid 38406708)
43. Bergemann N, Mundt C, Parzer P et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr. Res. 74(2-3), 125-134 (2005). (Pubitemid 40255071)
44. Sanchez MG, Bourque M, Morissette M, Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16(3), e43-e71 (2010).
45. Guest PC, Schwarz E, Krishnamurthy D et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology DOI: 10.1016/j. psyneuen.2010.12.018 (2011) (Epub ahead of print).
46. Ferree NK, Kamat R, Cahill L. Influences of menstrual cycle position and sex hormone levels on spontaneous intrusive recollections following emotional stimuli. Conscious Cogn. DOI: 10.1016/j. concog.2011.02.003 (2011) (Epub ahead of print).
47. Moffat SD. Effects of testosterone on cognitive and brain aging in elderly men. Ann. NY Acad. Sci. 1055, 80-92 (2005). (Pubitemid 43211667)
48. Mendrek A. Reversal of normal cerebral sexual dimorphism in schizophrenia: evidence and speculations. Med. Hypotheses 69(4), 896-902 (2007). (Pubitemid 47248110)
49. Kline NS, Blair J, Cooper TB et al. A controlled seven year study of endocrine and other indices in drug treated chronic schizophrenics. Acta Psychiatr. Scand. Suppl. 206, 7-75 (1968).
50. Rinieris P, Markianos M, Hatzimanolis J, Stefanis C. A psychoendocrine study in male paranoid schizophrenics with delusional ideas of homosexual content. Acta Psychiatr. Scand. 72(3), 309-314 (1985). (Pubitemid 16257040)
51. Oades RD, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19(4), 373-385 (1994). (Pubitemid 24150549)
52. Ceskova E, Prikryl R, Kasparek T. Testosterone in first-episode schizophrenia. Neuro Endocrinol. Lett. 28(6), 811-814 (2007).
53. Akhondzadeh S, Rezaei F, Larijani B et al. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr. Res. 84(2-3), 405-410 (2006).
54. Ko YH, Jung SW, Joe SH et al. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 32(4), 385-391 (2007).
55. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr. Res. 58(1), 69-74 (2002). (Pubitemid 35287285)
56. van Rijn S, Aleman A, de Sonneville L et al. Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms. Psychol. Med. 21, 1-8 (2011
57. Swaab DF, Garcia-Falgueras A. Sexual differentiation of the human brain in relation to gender identity and sexual orientation. Funct. Neurol. 24(1), 17-28 (2009).
58. Arnold AP. The organizational-activational hypothesis as the foundation for a unified theory of sexual differentiation of all mammalian tissues. Horm. Behav. 55(5), 570-578 (2009).
59. Cahill L, Gorski L, Belcher A, Huynh Q. The influence of sex versus sex-related traits on long-term memory for gist and detail from an emotional story. Conscious Cogn. 13(2), 391-400 (2004). (Pubitemid 38591451)
60. Wood JL, Heitmiller D, Andreasen NC, Nopoulos P. Morphology of the ventral frontal cortex: relationship to femininity and social cognition. Cereb. Cortex 18(3), 534-540 (2008). (Pubitemid 351264222)
61. Hausmann M, Schoofs D, Rosenthal HE, Jordan K. Interactive effects of sex hormones and gender stereotypes on cognitive sex differences - a psychobiosocial approach. Psychoneuroendocrinology 34(3), 389-401 (2009).
62. Faludi G, Mirnics K. Synaptic changes in the brain of subjects with schizophrenia. Int. J. Dev. Neurosci. 29(3), 305-309 (2011).
63. Andreasen NC, Ehrhardt JC, Swayze VW 2nd et al. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch. Gen. Psychiatry 47(1), 35-44 (1990). (Pubitemid 20025544)
64. Reite M, Sheeder J, Teale P et al. Magnetic source imaging evidence of sex differences in cerebral lateralization in schizophrenia. Arch. Gen. Psychiatry 54(5), 433-440 (1997). (Pubitemid 27198205)
65. Gur RE, Cowell PE, Latshaw A et al. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch. Gen. Psychiatry 57(8), 761-768 (2000). (Pubitemid 30650111)
66. Flaum M, OLeary DS, Swayze VW 2nd et al. Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J. Psychiatr. Res. 29(4), 261-276 (1995).
67. Lauriello J, Hoff A, Wieneke MH et al. Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Am. J. Psychiatry 154(6), 819-825 (1997). (Pubitemid 27230105)
68. Schlaepfer TE, Harris GJ, Tien AY et al. Structural differences in the cerebral cortex of healthy female and male subjects: a magnetic resonance imaging study. Psychiatry Res. 61(3), 129-135 (1995).
69. Paus T, Otaky N, Caramanos Z et al. In vivo morphometry of the intrasulcal gray matter in the human cingulate, paracingulate, and superior-rostral sulci: hemispheric asymmetries, gender differences and probability maps. J. Comp. Neurol. 376(4), 664-673 (1996). (Pubitemid 27009847)
70. Harasty J, Double KL, Halliday GM, Kril JJ, McRitchie DA. Language-associated cortical regions are proportionally larger in the female brain. Arch. Neurol. 54(2), 171-176 (1997). (Pubitemid 27078724)
71. Goldstein JM, Seidman LJ, Horton NJ et al. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb. Cortex 11(6), 490-497 (2001). (Pubitemid 32488376)
72. Murphy DG, DeCarli C, McIntosh AR et al. Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Arch. Gen. Psychiatry 53(7), 585-594 (1996). (Pubitemid 26240861)
73. Allen LS, Hines M, Shryne JE, Gorski RA. Two sexually dimorphic cell groups in the human brain. J. Neurosci. 9(2), 497-506 (1989). (Pubitemid 19069494)
74. Agartz I, Saaf J, Wahlund LO, Wetterberg L. Quantitative estimations of cerebrospinal fluid spaces and brain regions in healthy controls using computer-assisted tissue classification of magnetic resonance images: relation to age and sex. Magn. Reson. Imaging 10(2), 217-226 (1992).
75. Zhou JN, Hofman MA, Gooren LJ, Swaab DF. A sex difference in the human brain and its relation to transsexuality. Nature 378(6552), 68-70 (1995).
76. Goldstein JM, Seidman LJ, OBrien LM et al. Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance imaging. Arch. Gen. Psychiatry 59(2), 154-164 (2002). (Pubitemid 34137386)
77. Takahashi T, Suzuki M, Kawasaki Y et al. Perigenual cingulate gyrus volume in patients with schizophrenia: a magnetic resonance imaging study. Biol. Psychiatry 53(7), 593-600 (2003). (Pubitemid 36385061)
78. Takahashi T, Suzuki M, Zhou SY et al. Lack of normal gender differences of the perigenual cingulate gyrus in schizophrenia spectrum disorders. A magnetic resonance imaging study. Eur. Arch. Psychiatry Clin. Neurosci. 254(5), 273-280 (2004). (Pubitemid 39312821)
79. Gur RC, Gunning-Dixon FM, Turetsky BI, Bilker WB, Gur RE. Brain region and sex differences in age association with brain volume: a quantitative MRI study of healthy young adults. Am. J. Geriatr. Psychiatry 10(1), 72-80 (2002). (Pubitemid 34052905)
80. Gur RE, Kohler C, Turetsky BI et al. A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia. Biol. Psychiatry 55(5), 512-517 (2004). (Pubitemid 38338539)
81. Frazier JA, Hodge SM, Breeze JL et al. Diagnostic and sex effects on limbic volumes in early-onset bipolar disorder and schizophrenia. Schizophr. Bull. 34(1), 37-46 (2008). (Pubitemid 350262289)
82. Killgore WD, Yurgelun-Todd DA. Sex differences in amygdala activation during the perception of facial affect. Neuroreport 12(11), 2543-2547 (2001). (Pubitemid 32682218)
83. Schneider F, Habel U, Kessler C, Salloum JB, Posse S. Gender differences in regional cerebral activity during sadness. Hum. Brain Mapp. 9(4), 226-238 (2000). (Pubitemid 30194718)
84. Canli T, Desmond JE, Zhao Z, Gabrieli JD. Sex differences in the neural basis of emotional memories. Proc. Natl Acad. Sci. USA 99(16), 10789-10794 (2002).
85. Lee TM, Liu HL, Hoosain R et al. Gender differences in neural correlates of recognition of happy and sad faces in humans assessed by functional magnetic resonance imaging. Neurosci. Lett. 333(1), 13-16 (2002). (Pubitemid 35223591)
86. Lee TM, Liu HL, Chan CC, Fang SY, Gao JH. Neural activities associated with emotion recognition observed in men and women. Mol. Psychiatry 10(5), 450-455 (2005). (Pubitemid 40646433)
87. Wrase J, Klein S, Gruesser SM et al. Gender differences in the processing of standardized emotional visual stimuli in humans: a functional magnetic resonance imaging study. Neurosci. Lett. 348(1), 41-45 (2003). (Pubitemid 37271932)
88. Fischer AH, Rodriguez Mosquera PM, van Vianen AE, Manstead AS. Gender and culture differences in emotion. Emotion 4(1), 87-94 (2004).
89. Hofer A, Siedentopf CM, Ischebeck A et al. Gender differences in regional cerebral activity during the perception of emotion: a functional MRI study. Neuroimage 32(2), 854-862 (2006). (Pubitemid 44149154)
90. Thomsen T, Hugdahl K, Ersland L et al. Functional magnetic resonance imaging (fMRI) study of sex differences in a mental rotation task. Med. Sci. Monit. 6(6), 1186-1196 (2000). (Pubitemid 32009583)
91. Jordan K, Wustenberg T, Heinze HJ, Peters M, Jancke L. Women and men exhibit different cortical activation patterns during mental rotation tasks. Neuropsychologia 40(13), 2397-2408 (2002). (Pubitemid 35300164)
92. Weiss E, Siedentopf CM, Hofer A et al. Sex differences in brain activation pattern during a visuospatial cognitive task: a functional magnetic resonance imaging study in healthy volunteers. Neurosci. Lett. 344(3), 169-172 (2003). (Pubitemid 36694670)
93. Hugdahl K, Thomsen T, Ersland L. Sex differences in visuo-spatial processing: an fMRI study of mental rotation. Neuropsychologia 44(9), 1575-1583 (2006). (Pubitemid 43849860)
94. Crespo-Facorro B, Paradiso S, Andreasen NC et al. Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odors. JAMA 286(4), 427-435 (2001). (Pubitemid 32681485)
95. Paradiso S, Andreasen NC, Crespo-Facorro B et al. Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am. J. Psychiatry 160(10), 1775-1783 (2003). (Pubitemid 41103310)
96. Guillem F, Mograss M. Gender differences in memory processing: evidence from event-related potentials to faces. Brain Cogn. 57(1), 84-92 (2005). (Pubitemid 40040535)
97. Guillem F, Mendrek A, Lavoie ME, Pampoulova T, Stip E. Sex differences in memory processing in schizophrenia: an event-related potential (ERP) study. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(1), 1-10 (2009).
98. Mendrek A, Mancini-Marie A, Fahim C, Stip E. Sex differences in the cerebral function associated with processing of aversive stimuli by schizophrenia patients. Aust. NZ J. Psychiatry 41(2), 136-141 (2007). (Pubitemid 46705625)
99. Mendrek A, Mancini-Mare A, Jiménez J et al. Sex differences in the processing of positive and negative affect in schizophrenia: an fMRI and ERP study. Schizophrenia Bull. 35(S1), 164 (2009).
100. Jiménez JA, Mancini-Mare A, Lakis N, Rinaldi M, Mendrek A. Disturbed sexual dimorphism of brain activation during mental rotation in schizophrenia. Schizophr. Res. 122(1-3), 53-62 (2010).
101. Kulkarni J, de Castella A, Smith D et al. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20(3), 247-252 (1996). (Pubitemid 26232968)
102. Kulkarni J, Riedel A, de Castella AR et al. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 48(1), 137-144 (2001). (Pubitemid 32241189)
103. Kulkarni J, de Castella A, Fitzgerald PB et al. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 65(8), 955-960 (2008).
104. Akhondzadeh S, Nejatisafa AA, Amini H et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(6), 1007-1012 (2003). (Pubitemid 37141389)
105. Kulkarni J, de Castella A, Headey B et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr. Res. 125(2-3), 278-283 (2011).
106. Ko YH, Lew YM, Jung SW et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 28(4), 375-383 (2008).
107. Elias A, Kumar A. Testosterone for schizophrenia. Cochrane Database Syst. Rev. 3, CD006197 (2007).
108. Cahill L. Sex influences on brain and emotional memory: the burden of proof has shifted. Prog. Brain Res. 186, 29-40 (2010).
109. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol. Reprod. 67(5), 1379-1385 (2002). (Pubitemid 35204912)
110. Ciriza I, Carrero P, Azcoitia I, Lundeen SG, Garcia-Segura LM. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J. Neurobiol. 61(2), 209-221 (2004). (Pubitemid 39426147)
111. Zhao L, ONeill K, Brinton RD. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J. Pharmacol. Exp. Ther. 319(3), 1124-1132 (2006).
112. Cyr M, Calon F, Morissette M et al. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr. Pharm. Des. 6(12), 1287-1312 (2000). (Pubitemid 30604736)
113. Kulkarni J, Gurvich C, Lee SJ et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35(8), 1142-1147 (2010).
114. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T. Neuroprotective properties of 17b-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41(2), 131-138 (2001).
115. Wright DW, Kellermann AL, Hertzberg VS et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49(4), 391-402, e391-e392 (2007).
116. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 12(2), R61 (2008).
117. Strous RD. Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology. Essent. Psychopharmacol. 6(3), 141-147 (2005).
118. Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci. Ther. 16(1), 32-44 (2010).
119. Strous RD, Maayan R, Lapidus R et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 60(2), 133-141 (2003). (Pubitemid 36173119)
120. Ritsner MS, Gibel A, Shleifer T et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 71(10), 1351-1362 (2010).
121. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychopharmacol. 26(5), 495-499 (2006). (Pubitemid 44401470)
122. Strous RD, Stryjer R, Maayan R et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32(2), 96-105 (2007). (Pubitemid 46274013)